It demonstrated potential therapeutic effect for many diseases attributed to NADPH-oxidase inhibition, including arthritis [3], [4], asthma [8], [9], stroke [6], [10], arteriosclerosis [11], and acute lung injury [12]–[16]. Here, FMO5 is linked to asthma.